Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9789MR)

This product GTTS-WQ9789MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Hypercholesterolemia research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ9789MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12243MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ6554MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA D2E7
GTTS-WQ10334MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY 3090106
GTTS-WQ13199MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ4586MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986004
GTTS-WQ2230MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aVWF81
GTTS-WQ6709MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DS 1024
GTTS-WQ6002MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CNTO 095
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW